Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sees Unusually-High Trading Volume – Here’s Why

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) saw unusually-high trading volume on Thursday. 166,025 shares were traded during trading, a decline of 13% from the previous session’s volume of 190,495 shares. The stock last traded at $29.49 and had previously closed at $30.00.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on LKFT shares. TD Cowen assumed coverage on Lakefront Biotherapeutics American Depositary Shares in a research report on Friday, August 21st. They issued a “buy” rating on the stock. UBS Group raised shares of Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a report on Wednesday, September 23rd. Morgan Stanley decreased their target price on shares of Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 11th. Royal Bank Of Canada raised shares of Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $26.00 to $45.00 in a report on Wednesday, September 23rd. Finally, Weiss Ratings upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.00.

Lakefront Biotherapeutics American Depositary Shares Stock Up 0.7%

The firm has a market capitalization of $1.96 billion, a PE ratio of -21.09 and a beta of 0.24. The stock has a 50-day moving average price of $28.51 and a 200 day moving average price of $28.65.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its earnings results on Monday, August 10th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $1.00. The business had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $7.29 million. As a group, equities analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -1.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LKFT. ABC Arbitrage SA acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 1st quarter worth about $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Lakefront Biotherapeutics American Depositary Shares in the 1st quarter worth about $248,000. QRG Capital Management Inc. increased its stake in Lakefront Biotherapeutics American Depositary Shares by 21.9% during the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after buying an additional 3,535 shares in the last quarter. Finally, Madison Avenue Partners LP increased its stake in Lakefront Biotherapeutics American Depositary Shares by 0.8% during the 4th quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock worth $72,371,000 after buying an additional 17,394 shares in the last quarter. 32.46% of the stock is owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.